BUSINESS COMBINATIONS - Narrative (Details) - USD ($) $ in Millions							3 Months Ended		12 Months Ended
	Oct. 01, 2024	Sep. 30, 2024	Aug. 19, 2024	Aug. 18, 2024	Jul. 22, 2024	Feb. 28, 2023	Dec. 31, 2024	Sep. 30, 2024	Dec. 31, 2024
Innovalve Bio Medical Limited
Business Acquisition [Line Items]
Cash consideration paid at closing	$ 319.3	$ 30.0
Fair value of previously held equity interest	$ 64.6	$ 3.5
Percentage of previously held interest		4.00%						4.00%
Equity interest in acquire, excluding initial acquisition, percentage	96.00%
Step acquisition, equity interest in acquire, remeasurement gain							$ 30.5
Total purchase price, net of cash acquired	$ 380.9
Payments to acquire businesses	298.2
Cash acquired	21.1
Settlement of pre-existing relationships	5.4
Fair value of contingent consideration	12.7
Additional milestone driven contingent consideration liability	$ 25.0
Milestone achievement period	5 years
Business combination, escrow deposit	$ 34.6
Acquisition-related costs									$ 2.3
Additional research and development expenditures to be incurred prior to product introduction	$ 74.3
Innovalve Bio Medical Limited | In-process research and development | Discount Rate
Business Acquisition [Line Items]
Measurement input	10.50%
Endotronix, Inc
Business Acquisition [Line Items]
Cash consideration paid at closing			$ 650.3	$ 60.0
Fair value of previously held equity interest			$ 94.6	$ 10.0
Percentage of previously held interest				7.00%
Equity interest in acquire, excluding initial acquisition, percentage			93.00%
Step acquisition, equity interest in acquire, remeasurement gain								$ 24.6
Total purchase price, net of cash acquired			$ 798.8
Payments to acquire businesses			649.1
Cash acquired			1.2
Settlement of pre-existing relationships			53.1
Fair value of contingent consideration			2.0
Business combination, escrow deposit			35.0
Acquisition-related costs									6.0
Additional research and development expenditures to be incurred prior to product introduction			$ 47.1
Endotronix, Inc | In-process research and development | Discount Rate
Business Acquisition [Line Items]
Measurement input			18.00%
Endotronix, Inc | Developed technology | Discount Rate
Business Acquisition [Line Items]
Measurement input			15.50%
JC Medical, Inc.
Business Acquisition [Line Items]
Cash consideration paid at closing					$ 114.8
Total purchase price, net of cash acquired					116.3
Cash acquired					0.3
Fair value of contingent consideration					1.8
Business combination, escrow deposit					12.0
Acquisition-related costs									$ 1.6
Additional research and development expenditures to be incurred prior to product introduction			$ 55.8
Potential milestone-driven payments					$ 200.0
Contingent consideration liability, term					12 years
Escrow deposit, holding period					15 months
JC Medical, Inc. | In-process research and development | Discount Rate
Business Acquisition [Line Items]
Measurement input					15.00%
Medical Technology Company
Business Acquisition [Line Items]
Additional research and development expenditures to be incurred prior to product introduction						$ 68.6
Medical Technology Company | Variable Interest Entity, Primary Beneficiary
Business Acquisition [Line Items]
Payments to acquire businesses						169.0
Cash acquired						$ 6.8
Percentage of interest acquired						61.00%